Hsa_circRNA_0000518 facilitates breast cancer development via regulation of the miR-326/FGFR1 axis.

abstract：BACKGROUND:Scutellarin (SCU), a flavonoid isolated from Erigeron breviscapus (Vant.) Hand.-Mazz., increases autophagy and apoptosis in the adenocarcinoma A549 cell line, which is resistant to cisplatin. However, whether SCU alone has antitumor activity against non-small cell lung cancer (NSCLC) is unknown. METHODS:Cel...

journal_title：Thoracic cancer

authors： Cao P,Liu B,Du F,Li D,Wang Y,Yan X,Li X,Li Y

更新日期：2019-03-01 00:00:00

abstract：:Fundamental treatment for papillary thyroid carcinoma (PTC) involves total or subtotal thyroidectomy. Iodine-131 ((131)I) is routinely utilized to target remnant thyroid cancer and metastasis after thyroidectomy. The effectiveness of other therapeutic modalities remains unsatisfactory; thus, these patients have a poor...

journal_title：Thoracic cancer

authors： Wang HJ,Yao JM,Zhang ZW,Zhao JY,Shang HX,Liao L,Dong JJ

更新日期：2015-11-01 00:00:00

abstract：BACKGROUND:Radiofrequency ablation and microwave ablation are frequently prescribed for thoracic cancer. However, few writers have been able to draw on any systematic research into the differences between the two ablation methods. METHODS:A literature search was carried out using Embase, PUBMED, Web of Science, Cochra...

journal_title：Thoracic cancer

authors： Sun YD,Zhang H,Liu JZ,Xu HR,Wu HY,Zhai HZ,Lu CY,Zhao X,Chen YQ,Zhou LL,Han JJ

更新日期：2019-03-01 00:00:00

abstract：:A mediastinal germ cell tumor with a sarcomatous component is extremely rare and is accompanied by a poor prognosis. Clinical and radiologic diagnosis is very difficult. Herein, we report a rare case of anterior mediastinal malignant teratoma containing a growing liposarcomatous component and detail the diagnostic pro...

journal_title：Thoracic cancer

authors： Lee HJ,Seon HJ,Choi YD

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Patients with malignant pleural effusion have a limited life expectancy. An increase in pleural and oncological treatment options and more accurate prognostic evaluation may help individualize treatment strategies. The aim of this study was to identify the prognostic indicators of overall survival (OS) after...

journal_title：Thoracic cancer

authors： Yoon DW,Cho JH,Choi YS,Kim J,Kim HK,Zo JI,Shim YM

更新日期：2016-07-01 00:00:00

abstract：:ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated re...

journal_title：Thoracic cancer

authors： Zhu YC,Zhou YF,Wang WX,Xu CW,Zhuang W,Du KQ,Chen G

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:The abundance of tumor infiltrating CD8 T cells is an important parameter for antitumor effect of PD-1/PD-L1 immune checkpoint inhibitors, which is less in epidermal growth factor receptor (EGFR) mutation than wild-type non-small cell lung cancer (NSCLC). The mechanism still requires further study. METHODS:...

journal_title：Thoracic cancer

authors： Zhao C,Su C,Li X,Zhou C

更新日期：2020-08-01 00:00:00

abstract：:A 57-year-old man was admitted to our department 10 years ago, diagnosed with tracheal adenoid cystic carcinoma. After discontinuing chemotherapy and radiotherapy, the disease recurred in December 2016. Apatinib mesylate (500 mg/day) was administered and computed tomography revealed that his symptoms were significantl...

journal_title：Thoracic cancer

authors： Wang H

更新日期：2017-11-01 00:00:00

abstract：:For refractory or resistant small cell lung cancer (SCLC), there is no standard treatment. We report a case of refractory SCLC achieving complete remission and then developing fatal interstitial pneumonitis after treatment with single-agent nab-paclitaxel. The relevant literature has also been reviewed. In terms of ef...

journal_title：Thoracic cancer

authors： Wang B,Yang J,Luo D,Qiao H,Xie Z,Zhang X,Wu Y

更新日期：2012-02-01 00:00:00

abstract：:We examined two cases of primary lung cancer with sebaceous-like clear cells (SLCCs), defined as clear carcinoma cells with microvacuolated cytoplasm and centrally located nuclei, which were selected from among 281 surgical/autopsy cases of lung cancer (2/281, 0.7%). Both cases were higher stage (stage IIA and IIIA), ...

journal_title：Thoracic cancer

authors： Matsukuma S,Obara K,Kono T,Takeo H,Sato K

更新日期：2013-11-01 00:00:00

abstract：BACKGROUND:Central airway obstruction related to endobronchial malignancy is one of the most difficult oncological complications and requires efficient palliative intervention. METHODS:Fifty-three consecutive patients with unresectable endobronchial malignancy receiving bronchoscopic cryotherapy as palliative treatmen...

journal_title：Thoracic cancer

authors： Kuo SC,Lo YL,Chou CL,Chung FT,Lin SM,Liu CY,Kuo HP

更新日期：2015-11-01 00:00:00

abstract：BACKGROUND:Uridine 5'-diphospho-glucuronosyltransferase 1A1 (UGT1A1*27) is known to impair the effect of UGT in basic research; however, little clinical investigation has been conducted. To evaluate the effect of the UGT1A1*27 polymorphism in irinotecan therapy, we conducted a prospective study. METHODS:Eligibility cr...

journal_title：Thoracic cancer

authors： Fukuda M,Suetsugu T,Shimada M,Kitazaki T,Hashiguchi K,Kishimoto J,Harada T,Seto T,Ebi N,Takayama K,Sugio K,Semba H,Nakanishi Y,Ichinose Y

更新日期：2016-07-01 00:00:00

abstract：BACKGROUND:The important role of angiogenesis displaying in tumor development and metastasis has been generally realized. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and endostatin (ES) are critical members of angiogenesis modulating the balance between pro-angiogenenic and anti-ang...

journal_title：Thoracic cancer

authors： Hu MM,Hu Y,Gao GK,Han Y,Shi GL,Li BL

更新日期：2015-07-01 00:00:00

abstract：BACKGROUND:We explored correlations between the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, epidermal growth factor receptor (EGFR) mutation status, and prognosis. METHODS:Data from 293 patients with lung adenocarcinoma were classifi...

journal_title：Thoracic cancer

authors： Guo Z,Yi F,Yin W,Zhang Y,Li Q,Gu Y,Xiao Y,Cao B,Ma L,Liang L

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:We investigated the effect of micro-RNA 24 (miR-24) and WWOX on non-small cell lung cancer (NSCLC) cell proliferation and migration in vitro and in vivo. METHODS:We performed bioinformatics analysis and 3' untranslated region luciferase assay to investigate the direct target of miR-24. Proliferation, apopto...

journal_title：Thoracic cancer

authors： Wang XH,Gan CZ,Xie JY

更新日期：2018-12-01 00:00:00

abstract：:After an initial benefit, non-small-cell lung cancer (NSCLC) patients receiving therapy with tyrosine kinase inhibitors develop drug resistance through a variety of mechanisms. Among these, tumor histology changes are a mechanism of acquired resistance in epidermal growth factor receptor-mutated and anaplastic lymphom...

journal_title：Thoracic cancer

authors： Mengoli MC,Orsi G,Lococo F,Grizzi G,Barbieri F,Bertolini F,Rossi G,Novello S

更新日期：2017-07-01 00:00:00

abstract：BACKGROUND:The standard of care for fit locally advanced non-small cell lung cancer (NSCLC) patients is concurrent chemoradiotherapy (CCRT). However, in a subset of patients with lung adenocarcinoma with mutant EGFR (LA-mEGFR), the role of EGFR-tyrosine kinase inhibitors (TKIs) is not clear. We compared CCRT versus TKI...

journal_title：Thoracic cancer

authors： Hsia TC,Liang JA,Li CC,Chien CR

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:Lung cancer is the leading cause of cancer-related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS...

journal_title：Thoracic cancer

authors： Kasahara N,Imai H,Naruse I,Tsukagoshi Y,Kotake M,Sunaga N,Kaira K,Maeno T,Asao T,Hisada T

更新日期：2020-08-01 00:00:00

abstract：:After sternal tumor resection, reconstruction of chest wall defects is still a challenging part of thoracic surgery. Three-dimensional (3D)-printed titanium alloy prosthesis implants provide an effective solution. The bionic bone trabecular micropore structure, which is beneficial to the human body, increases stabilit...

journal_title：Thoracic cancer

authors： Wang W,Liang Z,Yang S,Feng Q,Nie X,Su G,Yuan W,Han Y

更新日期：2020-11-01 00:00:00

abstract：BACKGROUND:This study aims to evaluate the incidence and characteristics of chyle leakage after curative oncologic esophagectomy, and the effectiveness of thoracic duct ligation. METHODS:This is a retrospective cohort study using the medical records of 1514 patients who underwent curative esophagectomy for esophageal ...

journal_title：Thoracic cancer

authors： Kim D,Cho J,Kim K,Shim YM

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better progno...

journal_title：Thoracic cancer

authors： Kang J,Chen HJ,Zhang XC,Su J,Zhou Q,Tu HY,Wang Z,Wang BC,Zhong WZ,Yang XN,Chen ZH,Ding Y,Wu X,Wang M,Fu JG,Yang Z,Zhang X,Shao YW,Wu YL,Yang JJ

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life-threatening adverse event. The purpose of this study was to evaluate whether the development of immune-related adverse events (irAEs), especially ILD, was associated with treatment efficacy and to research th...

journal_title：Thoracic cancer

authors： Sugano T,Seike M,Saito Y,Kashiwada T,Terasaki Y,Takano N,Hisakane K,Takahashi S,Tanaka T,Takeuchi S,Miyanaga A,Minegishi Y,Noro R,Kubota K,Gemma A

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Epidermal growth factor receptor (EGFR) activating mutations are usually associated with DNA damage repair (DDR) deficiency. However, the precise mechanism has remained elusive. In this study, we aimed to investigate whether EGFR exon 19 deletion mutation downstream signals contributed to DDR deficiency by d...

journal_title：Thoracic cancer

authors： Zhang L,Pradhan B,Guo L,Meng F,Zhong D

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:Lung cancer represents the highest morbidity and mortality caused by neoplasms in the world; therefore researchers continue to search for new tools to diagnose and treat the disease. The aim of the study was to establish the role of single nucleotide polymorphisms (SNP) in the promoter region of the human le...

journal_title：Thoracic cancer

authors： Kowal A,Wiśniewski A,Kuśnierczyk P,Jankowska R

更新日期：2015-09-01 00:00:00

abstract：:Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune-related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy-related adverse events. The most common symptoms are maculopapular rash and pru...

journal_title：Thoracic cancer

authors： Si X,He C,Zhang L,Liu X,Li Y,Wang H,Guo X,Zhou J,Duan L,Wang M,Zhang L

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:This study aimed to explore the effects of HMGA2 on cell proliferation and metastases in lung cancer and its underlying mechanism. METHODS:HMGA2 expression in lung cancer tissues and its association with overall survival were analyzed based on data from a public database. The roles of HMGA2 were validated v...

journal_title：Thoracic cancer

authors： Gao X,Dai M,Li Q,Wang Z,Lu Y,Song Z

更新日期：2017-09-01 00:00:00

abstract：BACKGROUND:Tumor recurrence or residual tumor after targeted therapy is common in patients with advanced non-small cell lung cancer (NSCLC). There is a lack of high-level evidence on which type of treatment should be employed for these patients and the role of salvage surgery has not been well reported in the literatur...

journal_title：Thoracic cancer

authors： Song W,Di S,Liu J,Fan B,Zhao J,Zhou S,Chen S,Dong H,Yue C,Gong T

更新日期：2020-04-01 00:00:00

abstract：:Patients undergoing hemodialysis (HD) are frequently elderly with poor performance status and usually cannot withstand chemotherapy because of its toxicities. We report a case of an elderly woman with chronic renal failure undergoing HD who was diagnosed with advanced non-small cell lung cancer and treated with orally...

journal_title：Thoracic cancer

authors： Luo J,Ni L,Wang M,Zhong W,Xiao Y,Zheng K,Hu P

更新日期：2016-03-01 00:00:00

abstract：BACKGROUND:The aim of this study was to report a single referral center experience in robotic extended thymectomy for clinical early stage thymomas, evaluating its safety, feasibility and efficacy, with special regard to oncological outcomes. METHODS:Between January 2009 and December 2012, we retrospectively selected ...

journal_title：Thoracic cancer

authors： Huang P,Ye B,Yang Y,Tantai JC,Zhao H

更新日期：2014-07-01 00:00:00

abstract：:Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD-1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD-L1, in which a complete response to nivolumab was sustained for >14 months. Immunohisto...

journal_title：Thoracic cancer

authors： Okamura K,Fukuda Y,Soda H,Ogawara D,Iwasaki K,Fuchi S,Suyama T,Yoshida M,Harada T,Fukuda M,Mukae H

更新日期：2018-01-01 00:00:00